Humacyte Inc (HUMA)vsVertex Pharmaceuticals Inc (VRTX)
HUMA
Humacyte Inc
$0.62
-0.97%
HEALTHCARE · Cap: $187.05M
VRTX
Vertex Pharmaceuticals Inc
$481.70
-0.34%
HEALTHCARE · Cap: $119.94B
Smart Verdict
WallStSmart Research — data-driven comparison
Vertex Pharmaceuticals Inc generates 605952% more annual revenue ($12.22B vs $2.02M). VRTX leads profitability with a 35.5% profit margin vs 0.0%. VRTX earns a higher WallStSmart Score of 68/100 (B-).
HUMA
Avoid14
out of 100
Grade: F
VRTX
Strong Buy68
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+44.2%
Fair Value
$1.81
Current Price
$0.62
$1.19 discount
Margin of Safety
+49.1%
Fair Value
$941.26
Current Price
$481.70
$459.56 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Keeps 36 of every $100 in revenue as profit
Strong operational efficiency at 38.1%
Earnings expanding 61.4% YoY
Safe zone — low bankruptcy risk
Large-cap with strong market position
Every $100 of equity generates 22 in profit
Areas to Watch
Trading at 12.5x book value
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Expensive relative to growth rate
Moderate valuation
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : HUMA
HUMA has a balanced fundamental profile.
Bull Case : VRTX
The strongest argument for VRTX centers on Profit Margin, Operating Margin, EPS Growth. Profitability is solid with margins at 35.5% and operating margin at 38.1%.
Bear Case : HUMA
The primary concerns for HUMA are Price/Book, EPS Growth, Market Cap. Debt-to-equity of 5.67 is elevated, increasing financial risk.
Bear Case : VRTX
The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
HUMA profiles as a value stock while VRTX is a mature play — different risk/reward profiles.
HUMA carries more volatility with a beta of 2.52 — expect wider price swings.
VRTX is growing revenue faster at 7.8% — sustainability is the question.
VRTX generates stronger free cash flow (1.3B), providing more financial flexibility.
Bottom Line
VRTX scores higher overall (68/100 vs 14/100), backed by strong 35.5% margins. HUMA offers better value entry with a 44.2% margin of safety. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Humacyte Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Humacyte Inc (HUMA) is a pioneering biotechnology company specializing in vascular and regenerative medicine, with a focus on the development of human acellular vessels (HAVs). These innovative off-the-shelf products address critical needs in vascular reconstruction and chronic disease management, enhancing patient outcomes while potentially lowering healthcare costs. Utilizing its advanced technology platform, Humacyte is strategically positioned to lead advancements in transplantation and tissue engineering, solidifying its role as a transformative force in the evolving medical therapies landscape.
Vertex Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?